Outcomes 2016 - Baylor Hamilton Heart and Vascular Hospital FY 2016 | Page 32

Specialized Interventional Procedures
Angioplasty related interventional procedures are a mainstay at Baylor Jack and
Jane Hamilton Heart and Vascular Hospital. Other terms commonly associated
with angioplasty are percutaneous coronary intervention (PCI), balloon
angioplasty, coronary angioplasty, coronary artery angioplasty, percutaneous
transluminal coronary angioplasty and heart artery dilatation. One of the areas
that cardiologists on the medical staff at Baylor Hamilton Heart and Vascular
Hospital are known for is the ability to treat patients with left main disease.
Patients with advanced coronary artery disease who have undergone various
procedures may be diagnosed with “unprotected” left main (ULM) disease. These
candidates are referred to the interventional cardiologists on the medical staff
for advanced treatment and procedures that have been refined through years of
research and innovation. With many clinical trials over the years involving drug-
eluting stents, left main disease can be treated at Baylor Hamilton Heart and
Vascular Hospital with experienced and skilled interventionalists.
Other services available to patients include:
• Advanced generation of stents
• Atrial septal defect (ASD) and patent foramen ovale (PFO) closure
• Balloon valve repair
• Cardiac assist devices – a variety of assist devices are offered including the
potential for patient enrollment in device studies
• Carotid stenting. Many of the recent-to-market stents were trialed at
Baylor Hamilton Heart and Vascular Hospital
• Coronary angioplasty and stenting
• Coronary atherectomy
• Peripheral angiography and angioplasty
• Peripheral atherectomy
• Unprotected Left Main Disease intervention
Physicians on the medical staff have published numerous articles on important
research regarding cardiac stents. The first drug-eluting stent in Texas was placed
in our catheterization lab as part of the very early years for the SIRIUS trial.*
The history of “firsts” continued in fiscal year 2016 with many first-to-market
post-FDA approval stents and valves. Typically, trials have included and
continued through fiscal year 2016:
• Treatment of coronary artery disease with the newest generations of drug-
eluting stents
• New dosing strategies for medications used to prevent clots in stents
• Gene therapy for coronary disease not treatable with balloons and stents
• Treatment of stenosis in the renal (kidney) arteries in patients